Research
Improve product results through targeted market research
A survey of Xcenda’s Managed Care Network shows that oncology is the number 1 therapeutic area where payers expect biosimilars to produce cost savings. Other findings uncovered in recent research include:
> 54% of oncologists surveyed at a market research meeting reported that they were “not at all aware” about FDA regulation and pending legislation surrounding biosimilars
> 88% of oncologists surveyed at a separate meeting said that they were “not at all familiar” with recent legislation on comparative effectiveness
Turn to AmerisourceBergen Specialty Group and Xcenda for immediate access to market data that can improve your product’s success. Our valuable, credible and actionable research can help you make more informed and timely decisions toward the commercialization of your product. New market research reports include:
> The Changing Cost of Cancer — Our annual report on oncology trends and how healthcare reform, the economy and changes in healthcare management will impact manufacturers, payers, providers and patients
> Payer Perspectives on Biosimilars — Primary and secondary research that depicts how private payers view the market entrance of new biosimilars
> Comparative Effectiveness — Private payer and physician perspectives on the future of comparative analysis, how it will impact coverage, reimbursement and patient care
Click here to view a full description of these three reports.
To learn more, complete the form below, email Xcenda's Research Director Barb Lennert or visit Xcenda online.